AstraZeneca plc (AZN) Given Hold Rating at Shore Capital
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reissued by investment analysts at Shore Capital in a research note issued to investors on Friday.
A number of other analysts also recently weighed in on AZN. Berenberg Bank restated a “buy” rating and issued a GBX 4,950 ($64.61) target price on shares of AstraZeneca plc in a report on Thursday, June 9th. Deutsche Bank AG restated a “buy” rating and issued a GBX 5,600 ($73.10) target price on shares of AstraZeneca plc in a report on Tuesday, June 14th. Jefferies Group upped their price target on shares of AstraZeneca plc from GBX 3,900 ($50.91) to GBX 4,100 ($53.52) and gave the company a “hold” rating in a report on Tuesday, June 14th. BNP Paribas reiterated an “outperform” rating and set a GBX 5,000 ($65.27) price target on shares of AstraZeneca plc in a report on Wednesday, June 15th. Finally, HSBC reiterated a “hold” rating and set a GBX 4,240 ($55.35) price target on shares of AstraZeneca plc in a report on Friday, June 17th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) opened at 5074.00 on Friday. The firm’s 50 day moving average is GBX 5,004.64 and its 200-day moving average is GBX 4,431.30. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The company’s market cap is GBX 64.19 billion.
The business also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were paid a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date of this dividend was Thursday, August 11th. This represents a yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.